Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G1-S transition in Ki-Ras-overexpressing transformed adrenocortical cells

Jean Luc Mazet, Martine Padieu, Hanan Osman, Gabrielle Maume, Patrick Mailliet, Norbert Dereu, Andrew Hamilton, François Lavelle, Saïd M. Sebti, Bernard F. Maume

Research output: Contribution to journalArticle

Abstract

To test the Kirsten-Ras (Ki-Ras) alternative prenylation hypothesis in malignant transformation, we used a novel farnesyltransferase inhibitor competitive to farnesyl-pyrophosphate, RPR130401, and a CaaX peptidomimetic geranylgeranyltransferase-1 inhibitor GGTI-298. In Ki-Ras-overexpressing transformed adrenocortical cells, RPR130401 at 1-10 μM inhibited very efficiently the [3H]farnesyl but not [3H]geranylgeranyl transfer to Ras. However, proliferation of these cells was only slightly sensitive to RPR130401 (IC50=30 μM). GGTI-298 inhibited the growth of these cells with an IC50 of 11 μM but cell lysis was observed at 15 μM. The combination of 10 μM RPR130401 and 10 μM GGTI-298 inhibited efficiently (80%) cell proliferation. These combined inhibitors but not each inhibitor alone blocked the cell cycle in G0/G1 and disrupted MAP kinase activation. Thus, combination of two inhibitors, at non-cytotoxic concentrations, acting on the farnesyl-pyrophosphate binding site of the farnesyltransferase and the CaaX binding site of the geranylgeranyltransferase-1 respectively is an efficient strategy for disrupting Ki-Ras tumorigenic cell proliferation. Copyright (C) 1999 Federation of European Biochemical Societies.

Original languageEnglish (US)
Pages (from-to)235-240
Number of pages6
JournalFEBS Letters
Volume460
Issue number2
DOIs
StatePublished - Oct 29 1999

Fingerprint

Farnesyltranstransferase
Phosphotransferases
Chemical activation
Cell Proliferation
Cell proliferation
Inhibitory Concentration 50
Binding Sites
Cells
Peptidomimetics
Prenylation
Cell Cycle
Growth
GGTI 298
farnesyl pyrophosphate

Keywords

  • Alternative pathway
  • Anti-proliferative effect
  • Farnesyltransferase
  • Geranylgeranyltransferase
  • Kirsten-Ras
  • Prenylation

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G1-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. / Mazet, Jean Luc; Padieu, Martine; Osman, Hanan; Maume, Gabrielle; Mailliet, Patrick; Dereu, Norbert; Hamilton, Andrew; Lavelle, François; Sebti, Saïd M.; Maume, Bernard F.

In: FEBS Letters, Vol. 460, No. 2, 29.10.1999, p. 235-240.

Research output: Contribution to journalArticle

Mazet, Jean Luc ; Padieu, Martine ; Osman, Hanan ; Maume, Gabrielle ; Mailliet, Patrick ; Dereu, Norbert ; Hamilton, Andrew ; Lavelle, François ; Sebti, Saïd M. ; Maume, Bernard F. / Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G1-S transition in Ki-Ras-overexpressing transformed adrenocortical cells. In: FEBS Letters. 1999 ; Vol. 460, No. 2. pp. 235-240.
@article{bab80515bdbe4651a92c2430e481ecd6,
title = "Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G1-S transition in Ki-Ras-overexpressing transformed adrenocortical cells",
abstract = "To test the Kirsten-Ras (Ki-Ras) alternative prenylation hypothesis in malignant transformation, we used a novel farnesyltransferase inhibitor competitive to farnesyl-pyrophosphate, RPR130401, and a CaaX peptidomimetic geranylgeranyltransferase-1 inhibitor GGTI-298. In Ki-Ras-overexpressing transformed adrenocortical cells, RPR130401 at 1-10 μM inhibited very efficiently the [3H]farnesyl but not [3H]geranylgeranyl transfer to Ras. However, proliferation of these cells was only slightly sensitive to RPR130401 (IC50=30 μM). GGTI-298 inhibited the growth of these cells with an IC50 of 11 μM but cell lysis was observed at 15 μM. The combination of 10 μM RPR130401 and 10 μM GGTI-298 inhibited efficiently (80{\%}) cell proliferation. These combined inhibitors but not each inhibitor alone blocked the cell cycle in G0/G1 and disrupted MAP kinase activation. Thus, combination of two inhibitors, at non-cytotoxic concentrations, acting on the farnesyl-pyrophosphate binding site of the farnesyltransferase and the CaaX binding site of the geranylgeranyltransferase-1 respectively is an efficient strategy for disrupting Ki-Ras tumorigenic cell proliferation. Copyright (C) 1999 Federation of European Biochemical Societies.",
keywords = "Alternative pathway, Anti-proliferative effect, Farnesyltransferase, Geranylgeranyltransferase, Kirsten-Ras, Prenylation",
author = "Mazet, {Jean Luc} and Martine Padieu and Hanan Osman and Gabrielle Maume and Patrick Mailliet and Norbert Dereu and Andrew Hamilton and Fran{\cc}ois Lavelle and Sebti, {Sa{\"i}d M.} and Maume, {Bernard F.}",
year = "1999",
month = "10",
day = "29",
doi = "10.1016/S0014-5793(99)01355-1",
language = "English (US)",
volume = "460",
pages = "235--240",
journal = "FEBS Letters",
issn = "0014-5793",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G1-S transition in Ki-Ras-overexpressing transformed adrenocortical cells

AU - Mazet, Jean Luc

AU - Padieu, Martine

AU - Osman, Hanan

AU - Maume, Gabrielle

AU - Mailliet, Patrick

AU - Dereu, Norbert

AU - Hamilton, Andrew

AU - Lavelle, François

AU - Sebti, Saïd M.

AU - Maume, Bernard F.

PY - 1999/10/29

Y1 - 1999/10/29

N2 - To test the Kirsten-Ras (Ki-Ras) alternative prenylation hypothesis in malignant transformation, we used a novel farnesyltransferase inhibitor competitive to farnesyl-pyrophosphate, RPR130401, and a CaaX peptidomimetic geranylgeranyltransferase-1 inhibitor GGTI-298. In Ki-Ras-overexpressing transformed adrenocortical cells, RPR130401 at 1-10 μM inhibited very efficiently the [3H]farnesyl but not [3H]geranylgeranyl transfer to Ras. However, proliferation of these cells was only slightly sensitive to RPR130401 (IC50=30 μM). GGTI-298 inhibited the growth of these cells with an IC50 of 11 μM but cell lysis was observed at 15 μM. The combination of 10 μM RPR130401 and 10 μM GGTI-298 inhibited efficiently (80%) cell proliferation. These combined inhibitors but not each inhibitor alone blocked the cell cycle in G0/G1 and disrupted MAP kinase activation. Thus, combination of two inhibitors, at non-cytotoxic concentrations, acting on the farnesyl-pyrophosphate binding site of the farnesyltransferase and the CaaX binding site of the geranylgeranyltransferase-1 respectively is an efficient strategy for disrupting Ki-Ras tumorigenic cell proliferation. Copyright (C) 1999 Federation of European Biochemical Societies.

AB - To test the Kirsten-Ras (Ki-Ras) alternative prenylation hypothesis in malignant transformation, we used a novel farnesyltransferase inhibitor competitive to farnesyl-pyrophosphate, RPR130401, and a CaaX peptidomimetic geranylgeranyltransferase-1 inhibitor GGTI-298. In Ki-Ras-overexpressing transformed adrenocortical cells, RPR130401 at 1-10 μM inhibited very efficiently the [3H]farnesyl but not [3H]geranylgeranyl transfer to Ras. However, proliferation of these cells was only slightly sensitive to RPR130401 (IC50=30 μM). GGTI-298 inhibited the growth of these cells with an IC50 of 11 μM but cell lysis was observed at 15 μM. The combination of 10 μM RPR130401 and 10 μM GGTI-298 inhibited efficiently (80%) cell proliferation. These combined inhibitors but not each inhibitor alone blocked the cell cycle in G0/G1 and disrupted MAP kinase activation. Thus, combination of two inhibitors, at non-cytotoxic concentrations, acting on the farnesyl-pyrophosphate binding site of the farnesyltransferase and the CaaX binding site of the geranylgeranyltransferase-1 respectively is an efficient strategy for disrupting Ki-Ras tumorigenic cell proliferation. Copyright (C) 1999 Federation of European Biochemical Societies.

KW - Alternative pathway

KW - Anti-proliferative effect

KW - Farnesyltransferase

KW - Geranylgeranyltransferase

KW - Kirsten-Ras

KW - Prenylation

UR - http://www.scopus.com/inward/record.url?scp=0032752610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032752610&partnerID=8YFLogxK

U2 - 10.1016/S0014-5793(99)01355-1

DO - 10.1016/S0014-5793(99)01355-1

M3 - Article

C2 - 10544242

AN - SCOPUS:0032752610

VL - 460

SP - 235

EP - 240

JO - FEBS Letters

JF - FEBS Letters

SN - 0014-5793

IS - 2

ER -